Electra Therapeutics priced its upsized $350 million IPO, positioning the inflammation-focused company for a more commercial-ready footing as it advances ipsoprubart (a pan-SIRP monoclonal antibody) in secondary hemophagocytic lymphohistiocytosis (sHLH). The listing adds to a heavy 2026 IPO window for biotech, underscoring investor appetite for late-stage risk—particularly in immunology and inflammation. Electra’s proceeds are earmarked for registrational Phase II/III work toward a potential BLA filing, with the company highlighting the intent to translate pipeline momentum into broader corporate capabilities. The capital influx also matters for trial execution: larger runway typically improves timelines, enrollment resilience, and manufacturing planning when registrational studies are underway. The broader market context is reinforced by separate reporting that total biopharma financings are running at a high year-to-date pace through August, with IPOs helping buoy aggregate capital formation. For startups and mid-stage developers, Electra’s debut contributes to a signaling effect on valuation expectations in inflammation and immune-mediated disease categories.